Advertisement
Research Article

Preclinical Evaluation of a Replication-Deficient Intranasal ΔNS1 H5N1 Influenza Vaccine

  • Julia Romanova equal contributor,

    equal contributor Contributed equally to this work with: Julia Romanova, Brigitte M. Krenn

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Brigitte M. Krenn equal contributor,

    equal contributor Contributed equally to this work with: Julia Romanova, Brigitte M. Krenn

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Markus Wolschek,

    Affiliations: Avir Green Hills Biotechnology AG, Vienna, Austria, Department of Surgery, University of Vienna Medical School, Vienna, Austria

    X
  • Boris Ferko,

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Ekaterina Romanovskaja-Romanko,

    Affiliation: Influenza Research Institute, Russian Academy of Medical Sciences, St. Petersburg, Russia

    X
  • Alexander Morokutti,

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Anna-Polina Shurygina,

    Affiliation: Influenza Research Institute, Russian Academy of Medical Sciences, St. Petersburg, Russia

    X
  • Sabine Nakowitsch,

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Tanja Ruthsatz,

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Bettina Kiefmann,

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Ulrich König,

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Michael Bergmann,

    Affiliation: Department of Surgery, University of Vienna Medical School, Vienna, Austria

    X
  • Monika Sachet,

    Affiliation: Department of Surgery, University of Vienna Medical School, Vienna, Austria

    X
  • Shobana Balasingam,

    Affiliation: Retroscreen Virology Ltd., Centre for Infectious Diseases, Bart's and the London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom

    X
  • Alexander Mann,

    Affiliation: Retroscreen Virology Ltd., Centre for Infectious Diseases, Bart's and the London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom

    X
  • John Oxford,

    Affiliation: Retroscreen Virology Ltd., Centre for Infectious Diseases, Bart's and the London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom

    X
  • Martin Slais,

    Affiliation: BioTest Ltd., Konarovice, Czech Republic

    X
  • Oleg Kiselev,

    Affiliation: Influenza Research Institute, Russian Academy of Medical Sciences, St. Petersburg, Russia

    X
  • Thomas Muster,

    Affiliations: Avir Green Hills Biotechnology AG, Vienna, Austria, Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria

    X
  • Andrej Egorov mail

    a.egorov@greenhillsbiotech.com

    Affiliation: Avir Green Hills Biotechnology AG, Vienna, Austria

    X
  • Published: June 19, 2009
  • DOI: 10.1371/journal.pone.0005984

About the Authors

Julia Romanova, Brigitte M. Krenn, Markus Wolschek, Boris Ferko, Alexander Morokutti, Sabine Nakowitsch, Tanja Ruthsatz, Bettina Kiefmann, Ulrich König, Thomas Muster, Andrej Egorov
Avir Green Hills Biotechnology AG, Vienna, Austria
Ekaterina Romanovskaja-Romanko, Anna-Polina Shurygina, Oleg Kiselev
Influenza Research Institute, Russian Academy of Medical Sciences, St. Petersburg, Russia
Shobana Balasingam, Alexander Mann, John Oxford
Retroscreen Virology Ltd., Centre for Infectious Diseases, Bart's and the London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom
Thomas Muster
Division of General Dermatology, Department of Dermatology, Medical University of Vienna, Vienna, Austria
Markus Wolschek, Michael Bergmann, Monika Sachet
Department of Surgery, University of Vienna Medical School, Vienna, Austria
Martin Slais
BioTest Ltd., Konarovice, Czech Republic

Corresponding Author

Email: a.egorov@greenhillsbiotech.com

Competing Interests

Avir Green Hills Biotechnology is a privately held biopharmaceutical company based in Vienna which draws its own knowledge in virology to develop and commercialize a vaccine approach targeting seasonal and pandemic influenza disease among other products in the pipeline. The primary objective of the projects FLUVACC (LSHB-CT-2005-518281) and Intranasal H5 Vaccine (SP5B-CT-2007-044512) related to this manuscript is the development of an intranasal live attenuated vaccine targeting pandemic influenza disease. Both projects are executed in collaboration with international partners, which form a consortium that is regulated by the projects' corresponding consortium agreements. The consortium agreement regulates the operational execution of the project, including protection, exploitation and use of knowledge. IIPR rights related to this manuscript are covered by the following IP rights: DelNs1 mutants are covered by patents from Avir Green Hills and Mount Sinai School of Medicine. Patent applications covering the technology platform of the influenza virus expression construct and virus amplification procedure are fully owned by Avir Green Hills Biotechnology. The patent application concerning the purification process is co-owned with Biaseparations d.r.o. All individuals named in the authorship list of this manuscript are either employees of Avir Green Hills Biotechnology or of organizations that have entered an agreement within the European grants mentioned above.

Author Contributions

Conceived and designed the experiments: JR BMK MW BF TR MMB SB AM JO MS OK TM AE. Performed the experiments: BMK MW BF ERR AM APS SN BK UK MS MS. Analyzed the data: JR BMK BF ERR AM APS SN TR BK UK MS TM. Contributed reagents/materials/analysis tools: MW MMB. Wrote the paper: JR BMK AE.